Wahida, Adam http://orcid.org/0000-0002-8856-8834
Buschhorn, Lars http://orcid.org/0000-0001-7162-816X
Fröhling, Stefan
Jost, Philipp J.
Schneeweiss, Andreas
Lichter, Peter
Kurzrock, Razelle
Article History
Accepted: 14 October 2022
First Online: 24 November 2022
Competing interests
: A.W., L.B. and P.L. declare no competing interests. S.F. has received consulting or advisory honoraria from Bayer, Illumina and Roche, honoraria from Eli Lilly, PharmaMar and Roche, research funding from AstraZeneca, Pfizer, PharmaMar and Roche, and travel or accommodation expenses from Eli Lilly, Illumina, PharmaMar and Roche. P.J.J. has had a consulting or advisory role for and has received honoraria, research funding and/or travel/accommodation expenses from Ariad, Abbvie, Bayer, Boehringer Ingelheim, Novartis, Pfizer, Servier, Roche, Celgene (Bristol Myers Squibb), Pierre Fabre, Janssen (Johnson & Johnson) and MSD. A.S. has received research grants from Celgene, Roche and AbbVie, honoraria from Roche, Celgene, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Eli Lilly, GlaxoSmithKline, Seagen, Gilead Sciences, Bayer, Amgen, Pierre Fabre, streamedup!, promedicis, onkowissen.de, Metaplan and Connect Media, and travel support from Roche, Celgene and Pfizer. R.K. has received research funding from Biological Dynamics, Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant Health, Incyte, Konica Minolta, Medimmune (AstraZeneca), Merck Serono, Omniseq, Pfizer, Sequenom, Takeda and TopAlliance, has received consultant and/or speaker fees and/or has been an advisory board member for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, Daiichi Sankyo, Eisai, EOM Pharmaceuticals, Iylon, Merck, NeoGenomics, NEOMED, Pfizer, Prosperdtx, Roche, TD2/Volastra, Turning Point Therapeutics and X-Biotech, has an equity interest in CureMatch, CureMetrix and IDbyDNA, serves on the board of CureMatch and CureMetrix, and co-founded CureMatch.